Edgestream Partners L.P. Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Edgestream Partners L.P. grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 184.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 258,605 shares of the biopharmaceutical company’s stock after buying an additional 167,735 shares during the period. Edgestream Partners L.P.’s holdings in Amicus Therapeutics were worth $2,762,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Xponance Inc. raised its position in shares of Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. grew its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the last quarter. Finally, OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $26,000.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. This trade represents a 0.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $9.98 on Monday. The company’s fifty day simple moving average is $10.70 and its two-hundred day simple moving average is $10.60. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm has a market cap of $2.98 billion, a PE ratio of -29.35 and a beta of 0.68.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Bank of America increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.